

ABBREVIATIONS

ACA Affordable Care Act	IND Investigational new drug	RIF/RTP Rifampin/rifapentine
AI Artificial Intelligence	INH Isoniazid	ROI Return on investment
API Active pharmaceutical ingredient	INSTI Integrase Strand Transfer Inhibitor	RPV Rilpivirine
ART Antiretroviral therapy	IP Intellectual property	RPT Rifapentine
ARV Antiretroviral	IPT Isoniazid prevention treatment	RTI Reverse transcriptase inhibitor
AST/ALT Aspartate aminotransferase/Alanine aminotransferase	ISL Islatrovir	SAD Single ascending dose
ATQ/PGN Atovaquone/proguanil	ISL/ULO Islatravir/ulonivirine	SC Subcutaneous
AUC Area under the curve	ISR Injection site reaction	SD Single dose
AZT Zidovudine	JHU Johns Hopkins University	SoC Standard of care
AZT/3TC Zidovudine/Lamivudine	KP Key population	SQVr Saquinavir boosted with ritonavir
BDQ Bedaquiline	LA Long-acting	SR Sustained release
BE Bioequivalence	LAI Long-acting injectable	SRA Supervisory authority
B/F/TAF Bictegravir/emtricitabine/tenofovir alafenamide	LAPaL Long-acting therapeutics, patents, and licenses	SS Steady state
BMI Body mass index	LEAP Long-acting extended release antiretroviral research program	SSA sub-Saharan Africa
bnAbs Broadly neutralizing antibodies	LEN Lenacapavir	TAP Translation Accelerator Program
CAB Cabotegravir	LMIC Low-middle income country	TB Tuberculosis
CDMO Contract development and manufacturing organization	LTBI Latent TB infection	TDF Tenofovir
CELT Centre of Excellence for Long-acting Therapeutics	LRTI Lower respiratory tract infection	TE Therapeutic equivalence
CFU Colony-forming units	mAbs Monoclonal antibodies	TEAE Treatment-emergent AE
CHAI Clinton Health Access Initiative	MAD Multiple ascending dose	TLC-ART Targeted long-acting and combination antiretroviral therapy
DAIDS (NIH) Division of AIDS	MAP Microarray patch	TLD Tenofovir, lamivudine, and dolutegravir
DCE Discrete choice experiment	MMV Medicines for Malaria Venture	TLE Tenofovir, lamivudine, efavirenz
DcNP Drug combination nanoparticles	MPP Medicines Patent Pool	TPP Target product profile
DDI Drug-drug interaction	nano DDI nanofluidic drug delivery implant	ULA Ultra-long-acting
DOR Doravirine	NIH National Institutes of Health	ULO Ulonivirine
DPV Dapivirine	NOT (NIH) Notice	UPC User preferences core
DR Drug-sensitive	NP Nanoparticle	VAS Visual analog scale
DS Drug-resistant	NVP Nevirapine	WHO World Health Organization
DSD Differentiated service delivery	N6LS Modified N6 bNAb	YRGCARE YR Gaitonde Centre for AIDS Research and Education
DTG Dolutegravir	OAR (NIH) Office of AIDS Research	1HP 1 month of once-weekly INH/RPT
ER Extended release	PAR (NIH) Program Announcement	3HP 3 months of once-weekly INH/RPT
FDA Food and Drug Administration	PBPk Physiologically based pharmacokinetic	3TC Lamivudine
FDC Fixed-dose combination	PD Pharmacodynamics	
FTC Emtricitabine	PEPFAR	
FY Fiscal year	PGLA Polyglycolic acid	
GF Global Fund	PI Protease inhibitors	
GHSD Bureau of Global Health Security & Diplomacy	PIP Pediatric investigation plan	
G/P Glecaprevir/pibrentasvir	PK Pharmacokinetics	
GLP Good laboratory practice	PLWH People living with HIV	
GMP Good manufacturing practice	PP Paliperidone palmitate	
HBc HBV core	PPPY Per person per year	
HBs HBV surface	PrEP Pre-exposure prophylaxis	
HBsAg HBV surface antigen	PSI Protein synthesis inhibitor	
HBV Hepatitis C virus	PSP Pediatric study plan	
HCV Hepatitis C virus	PWID People who inject drugs	
HIV Human immunodeficiency virus	Q2M Every 2 months	
IgG Immunoglobulin G	Q4M Every 4 months	
IM Intramuscular	Q6M Every 6 months	
	RA Regulatory authority	
	RAL Raltegravir	